275 related articles for article (PubMed ID: 12546565)
21. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
22. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations.
Gund TM; Floyd J; Jung D
J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980
[TBL] [Abstract][Full Text] [Related]
23. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
[TBL] [Abstract][Full Text] [Related]
24. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase.
Venkatarangan P; Hopfinger AJ
J Med Chem; 1999 Jun; 42(12):2169-79. PubMed ID: 10377222
[TBL] [Abstract][Full Text] [Related]
25. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
Xiao Z; Varma S; Xiao YD; Tropsha A
J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
[TBL] [Abstract][Full Text] [Related]
26. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
Xiao J; Guo Z; Guo Y; Chu F; Sun P
Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
[TBL] [Abstract][Full Text] [Related]
28. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
29. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
30. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
31. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
32. Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors.
Mor M; Rivara S; Lodola A; Lorenzi S; Bordi F; Plazzi PV; Spadoni G; Bedini A; Duranti A; Tontini A; Tarzia G
Chem Biodivers; 2005 Nov; 2(11):1438-51. PubMed ID: 17191945
[TBL] [Abstract][Full Text] [Related]
33. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
Awale M; Mohan CG
J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
[TBL] [Abstract][Full Text] [Related]
34. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
35. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-VeitÃa M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
36. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
Martin E; Mukherjee P; Sullivan D; Jansen J
J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
[TBL] [Abstract][Full Text] [Related]
37. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
38. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
39. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
Dhanachandra Singh Kh; Karthikeyan M; Kirubakaran P; Nagamani S
J Mol Graph Model; 2011 Sep; 30():186-97. PubMed ID: 21831680
[TBL] [Abstract][Full Text] [Related]
40. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
